Purpose: To evaluate the tolerability of four alternating cisplatin-gemcitabine schedules. A secondary aim was to evaluate the clinical efficacy of this combination.
Introduction
Combination chemotherapy with gemcitabine and cisplatin is active in various solid tumors [1] . Sequence dependent pharmacokinetic and pharmacodynamic interactions between both drugs have been observed both preclinically and clinically [2] [3] [4] [5] [6] [7] . The influence of scheduling on toxicity and efficacy warrants further study in order to find the best regimen with an optimal therapeutic index.
Gemcitabine is attractive for combination chemotherapy, due to its multiple mechanisms of action [8, 9] and mild toxicity profile at an active dose [10] . Gemcitabine acts by incorporation of its triphosphate (dFdCTP) into DNA, subsequently leading to inhibition of exonuclease and DNA repair. Several selfpotentiating mechanisms have been described [8, 9] , enhancing the incorporation of dFdCTP into DNA and possibly also into RNA. Most phase II studies have been performed utilizing a weekly times three schedule, repeated every four weeks, with short-lived myelosuppression being the dose-limiting side effect [11, 12] . Efficacy has been observed in lung, bladder, breast, ovarian and pancreatic cancer.
Cisplatin acts by formation of platinum-DNA adducts Abbreviations: gem -gemcitabine at 800 mg/m 2 (30-min i.v.); ciscisplatin at 50 mg/m 2 (one-hour i.v.).
(Pt-DNA) [13] . A relation between the exposure to unbound cisplatin, Pt-DNA-adduct formation in white blood cells (WBC's) and tumor response in patients has been demonstrated [14, 15] . Currently, cisplatin is the basis of most of the effective combination chemotherapy regimens in testicular, lung, ovarian, bladder and head & neck squamous-cell carcinoma (HNSCC) [16] . Moreover, cisplatin is also active in stomach and esophageal carcinoma [17, 18] . Cisplatin induces mainly non-hematological side effects such as gastrointestinal-, oto-, nephroand neurotoxicity [19] . Preclinical studies on the gemcitabine-cisplatin combination showed schedule dependent additive and synergistic effects [2] [3] [4] [5] [6] . Five cell lines from a different histologic origin (ovarian, colon, and lung cancer) showed synergism at simultaneous exposure for twentyfour and seventy-two hours, four-hour exposure times showed additivity and synergism [2] [3] [4] . Both sequential schedules (gemcitabine before cisplatin and cisplatin before gemcitabine) were equally synergistic. In vivo studies indicated a small advantage of the gemcitabine four hours before cisplatin schedule over the reversed or simultaneous schedules when given at multiple doses [5, 6] , while with single injections, the best results were observed when cisplatin was given four hours before gemcitabine [5] . All schedules were more than additive in HNSCC xenografts [5] , non-small-cell lung cancer (NSCLC) [6] and in murine colon tumors [2] . However, a 24-hour interval for both sequences was too toxic. These studies indicated that synergism was dependent on exposure time to the drugs and was also schedule dependent.
Clinical studies were performed to evaluate this gemcitabine-cisplatin combination in various tumor types. In most studies gemcitabine (800-1500 mg/m 2 ) was given once weekly, 2 or 3 times, but cisplatin schedules varied considerably in these 21-28-day schedules. In patients with NSCLC different schedules of gemcitabine and cisplatin were tested in phase II studies and resulted in response rates as high as 54% [1, [20] [21] [22] [23] . However, the response rates and survival in these phase II studies cannot be compared directly since these are largely dependent on patient selection. Recently, three phase III studies in NSCLC showed response rates ranging from 31%-41%, with a median survival time of 8.7 months [24] [25] [26] [27] . In other malignancies, gemcitabine-cisplatin combinations also resulted in high response rates such as ovarian cancer [28, 29] , bladder cancer [30, 31] , and advanced HNSCC [32] . Although the gemcitabinecisplatin combination has been studied quite extensively, the clinical effect of gemcitabine-cisplatin scheduling regarding toxicity and efficacy, is not clear as yet.
In the present study we determined the tolerability and clinical efficacy of 4 alternating cisplatin-gemcitabine schedules, with 4-and 24-hour intervals.
Patients and methods

Patient selection
Patients eligible for this study were those with a histologically or cytologically confirmed diagnosis of a solid tumor at advanced stage, not amenable to established forms of treatment and with potential sensitivity for the gemcitabine-cisplatin combination. Disease had to be measurable or evaluable. Eligibility criteria included age ^ 18 years; a performance status =£2 according to the WHO scale; a life expectancy of ^ 3 months; adequate bone marrow function (WBC ? 3 x 10 9 / 1, absolute neutrophil count [ANC] >1.5 x 10 9 /l and platelet count 100 x 10 9 /l); adequate renal function (serum creatinine =S 120 umol/1 or creatinine clearance > 6 0 ml/min); adequate liver function (serum bilirubin <25 umol/1); adequate cardiac function; no second tumor; no brain metastasis. All patients had to give written informed consent before entering the study, which was approved by the ethical review board of the hospital.
Study design
Gemcitabine 800 mg/m 2 was administered as a 30-min infusion weekly for 3 weeks and cisplatin 50 mg/m 2 over 1 hour weekly for 2 weeks, every 28 days. Four schedules were studied sequentially: gemcitabine four hours before cisplatin, or vice versa and gemcitabine twenty-four hours before cisplatin, or vice versa (Table 1) . Each patient received the alternate sequence during the second and subsequent cycles. Patients were entered sequentially.
Pretreatment evaluation included medical history and clinical examination including performance status, length and weight. In addition, hematology and blood chemistry tests, ECG, chest X-ray, urine analysis and assessment of disease extent were performed.
Complete blood cell counts and serum creatinine were measured weekly and complete blood chemistry was performed before each treatment cycle. Toxicities were evaluated before each course and graded according to the NCI Common Toxicity Criteria (CTC). Treatment was delayed if the creatinine clearance <60 ml/min and/or if anŷ grade 3 WBC toxicity and/or ^ grade 2 thrombocytopenia occurred. However, in case WBC < 2 x 10 9 and/or platelets < 60 x I0 9 on day 15. the gemcitabine administration was omitted. Treatment was delayed until recovery of toxicity to a maximum of two weeks; in case of persisting toxicity. the patient went off study. Patients were followed for at least three weeks after the last drug dose and until recovery of all toxic effects. Dose modifications in case of toxicity were not allowed. Treatment was discontinued at disease progression, unacceptable drug toxicity or the patients' wish to stop the treatment. Usually, six cycles were given to responding patients and patients with stable disease.
Drugs
Gemcitabine (Gemzar": 2'.2'-difluoro-2'-deoxycytidine; Eli Lilly & Co, Indianapolis, IN. USA) was supplied as a lyophilised powder in sterile vials containing 200 or 1000 mg of gemcitabine as the hydrochloride salt, mannitol. and sodium acetate. Gemcitabine was administered in 500 ml normal saline, solutions contained less than 10 mg of gemcitabine in 1 ml of 0.9% sodium chloride. Gemcitabine was administered as a 30 min i.v. infusion. Gemcitabine infusion was given without antiemetics. Abbreviations gem -gemcitabine; cis -cisplatin; PS -performance status, CT -chemotherapy; RT -radiotherapy; NSCLC -non-small-cell lung cancer; SCLC -small-cell lung cancer; HNSCC -head and neck squamous-cell cancer. " Two patients received both prior CTand RT Cisplatin (cis-diamminedichloroplatinum(II)) was diluted in 500 ml hypertonic saline (2 9%) and given over one hour. Before cisplatin, patients received I.V. hydration with 1000 ml normal saline plus 20 mmol potassium chloride and 2 g magnesium sulphate over two hours. After cisplatin infusion 4000 ml normal saline plus 80 mmol potassium chloride and 8 g magnesium sulphate were given over 24 hours. Prophylactic antiemetics, 8 mg ondansetron and 8 mg dexamethason, were administered twice on the day of cisplatin infusion. In patients with insufficient urine production (<600 ml in six hours) 100 ml mannitol 20% i.v. was given, in case of insufficient effect this was repeated two hours later in combination with 10 mg of furosemide i.v.
Response criteria
Response to therapy was assessed according to World Health Organisation (WHO) criteria every two courses. Complete response (CR) was defined as the complete disappearance of all tumor lesions for at least four weeks. Partial response (PR) was defined as a reduction of > 50% in the product of the largest (perpendicular) diameters of the lesions while no new lesions as determined by two observations not less than four weeks apart. All other patients were considered non responders; progressive disease (PD) or stable disease (SD) which was defined as < 50% decrease and < 25% increase in the sum of the product of the largest perpendicular diameters of all measurable lesions with no appearance of new lesions, or progressive disease (PD). To qualify for response analysis, patients had to complete at least one cycle of treatment.
Toxicity analysis and statistics
Toxicity was evaluated according to the NCI Common Toxicity Criteria (CTC). Since patients received alternate sequences, and served as their own control, data could be evaluated using paired analysis. For WBC's, neutrophils and platelets total counts were evaluated. In addition, the percentage decrease in WBC and platelets was determined, using the following equation: percentage decrease = (pretreatment value -value of the nadir)/pretreatment value xl00%. To determine the effect of drug sequencing on hematological toxicity of the gemcitabine-cisplatin combinations, data of the first and the second cycle were compared, since patients made a cross-over from the first chemotherapy cycle to the next cycle, and pooled according to treatment schedule. Therefore we pooled the toxicity of gemcitabine four hours before cisplatin (cycle I of the first patient group and cycle II of the second patient group), and of cisplatin four hours before gemcitabine (cycle II of first patient group and cycle I of second patient group). The same was done for the 24-hour time interval. In addition we evaluated whether the 4-and 24-hour interval revealed any differences. The Kruskal-Wallis test was used to assess schedule dependency and in case of significant differences the Mann-Whitney U and Wilcoxon Signed Rank tests were used to compare unpaired (different time interval) and paired (same time interval) data of the four alternating schedules. In order to correct for differences in baseline characteristics between patients, we related patient characteristics (age, gender, tumor type, prior chemotherapy, prior platinum-based chemotherapy and prior radiotherapy) with the hematological toxicity by stepwise multiple linear regression. In addition the slope of the regression line and its 95% confidence interval were determined. The computer program SPSS (version 7.5, SPSS, Inc, Chicago, IL) was used for statistical analysis.
To determine the effect of scheduling on the non-hematological toxicity, patients were divided according to the schedule of the second and subsequent cycles. In case only one cycle could be given these patients were divided according to the received schedule. Statistics were done as noted above, using the Kruskal-Walhs test
Results
Forty-one patients entered the study between November 1995 and July 1997. Patient characteristics are listed in Table 2 . Thirty-eight of forty-one patients were assessable for response. Patients entered had a variety of tumors; ovarian, NSCLC, HNSCC and esophageal carcinoma being the most common. Twenty-six patients received prior chemotherapy, of which twenty-one platinumbased (all ovarian cancer, all cervical cancer, 1 SCLC and 5 NSCLC).
Hematologic toxicity
Myelotoxicity was the most important toxicity of the gemcitabine-cisplatin combination. Table 3 summarizes the grade 3 and 4 trombocytopenia of the first treatment cycle. Grade 3 and 4 trombocytopenia was not schedule dependent and was observed in 27 out of 41 patients (66%). No serious bleeding disorders occurred. During the first cycle, grade 3 and 4 leukopenia was less when gemcitabine was administered 24 hours before cisplatin as compared to the other 3 schedules (Table 3) . Overall, grade 3 and 4 leukopenia was observed in 19 out of 41 patients (46%). Neutropenic fever was observed in one patient who died of toxicity resulting from severe neutropenia and sepsis.
Since patients made a cross-over from the first chemotherapy cycle to the second cycle, we compared the toxicity of the first cycle with that of the second cycle. Thirty-four patients received at least two cycles of ther- apy. The data of 6 of the 34 patients were excluded from the hematological toxicity evaluation because 3 patients lacked a blood cell count measurement on day 15 and 3 patients received granulocyte-colony stimulating growth factor (G-CSF) during the second therapy cycle. Both, the platelet toxicity according to CTC and the percentage decrease in platelets did not differ significantly between the four studied schedules. Leukopenia was significantly different between the 4 groups (P -0.01); gemcitabine 24 hours before cisplatin was significantly less toxic compared to both cisplatin 4 hours before gemcitabine (P = 0.01) and cisplatin 24 hours before gemcitabine (P = 0.003), as determined by the MannWhitney U test. Moreover, a paired analysis of 28 data sets, 4 hours (16 sets) and 24 hours (12 sets), showed significantly more leukopenia when cisplatin preceded gemcitabine (P = 0.005). At the 4-hour time interval leukopenia was related to both age and gender, with more toxicity in older and female patients, whereas for the 24-hour time interval leukopenia was significantly worse when cisplatin was administered prior to gemcitabine, as determined by multiple linear regression (P = 0.001). With the same analysis, prior treatment was not related to toxicity. Furthermore, the percentage decrease in WBC was significantly higher when cisplatin was administered 24 hours before gemcitabine (P -0.002) when compared with the 3 other schedules. The neutrophils could not always be measured at day 15 and were evaluable in less patients (19 data sets); however a similar cytotoxicity pattern was observed as for the WBCs. Neutropenia was significantly worse when cisplatin was administered 24 hours prior to gemcitabine as compared to its reversed schedule (P = 0.04).
Anemia, defined as Hb =*6.0 mmol/1, led to blood transfusions in 63% of patients; 7 of 10, 6 of 14, 8 of 9 and 5 of 8 of patients treated with gemcitabine 4 hours prior to cisplatin, cisplatin 4 hours prior to gemcitabine, gemcitabine 24 hours prior to cisplatin and cisplatin 24 hours prior to gemcitabine, respectively. Myelotoxicity (mean of all patients ± SEM) was cumulative for both platelets (Figure la) , with day 15 values decreasing from 115 ± 13 in the first cycle to 60 ± 14 in the fourth cycle (P -0.0004), and for WBCs, with a more slight decrease in nadir values from 3.6 ± 0.4 in the first cycle to 2.3 ± 0.3 in the fourth cycle (P = 0.0004) (Figure lb) . Myelotoxicity led to a considerable number of omissions of gemcitabine on day 15 (Table 3) . This was not found to be schedule dependent and occurred in the first cycle in 26.7% of chemonaive patients and in 30.8% of chemotherapy pretreated patients. Overall, these percentages increased during subsequent treatment up to 42.1% after four cycles and 48.2% after six cycles and can be considered as an additional parameter for hematological toxicity. In 51% of the 143 administered cycles there were no day 15 omissions of gemcitabine. The mean number of cycles of chemotherapy administered per patient was 4.2 for gemcitabine 4 hours before cisplatin, 2.6 for the reversed schedule, 3.9 for gemcitabine 24 hours before cisplatin and 3.8 for the reversed schedule, respectively. Overall a mean number of 3.5 cycles was given, ranging from 1-8. 
Nonhematologic toxicity
Since no significant differences in non-hematological toxicity between the four schedules were found, a summary of the non-hematological toxicity is shown in Table 4 . Non-hematologic toxicity was mostly mild to moderate with only a few cases of grade 3 and 4 toxicity and was not different for the four schedules. Non-hematologic toxicity consisted mainly of grade 1 and 2 nausea/ vomiting and fatigue. Creatinine clearance, according to Cockroft-Gault, decreased slightly, although significantly from a pretreatment value of 79.1 ± 3.2 ml/min to 73.9 ± 3.6 ml/min after four cycles (P -0.01). Grade 3 pulmonary toxicity was observed in two patients; one patient developed a transient dyspnoea requiring oxygen support, three hours after only the first gemcitabine administration while the other patient had grade 3 pulmonary toxicity, although this occurred concurrently with bronchopneumonia. Most patients had mild hair loss; one patient had complete alopecia. In our experience, some particular gemcitabine related toxicities, such as elevated liver enzymes and flu-like syndrome were mild. It has been postulated that this may be due to the use of corticosteroids at the time of cisplatin administration. Peripheral edema was seen in seven patients of which in at least two cases this was tumor-related; the cause being thrombosis and axillary lymph nodes causing local edema after posthydration. Grade 3-4 neurotoxicity and ototoxicity were observed only once, both in patients pretreated with platinum-based chemotherapy.
Responses
Objective responses were observed in 9 of the 39 evaluable patients ( Abbreviations: CR -complete response; PR -partial response; SDstable disease; PD -progressive disease; NE -not evaluable, RRresponse rate; NSCLC -non-small-cell lung cancer; SCLC -smallcell lung cancer; HNSCC -head and neck squamous-cell carcinoma a Adenocarcinoma of unknown primary.
patients had a CR. The mean duration of response from the first assessment of PR, according to tumor type, was as follows: esophageal cancer (/? = 3) 6 months; ovarian cancer (/? = 2) 11 months; NSCLC (n = 1) 8 months; HNSCC (n -1) 2 months, melanoma (n = 1) 3 months and adenocarcinoma of unknown origin (n -1) 12 months. One patient with a CR had metastatic laryngeal carcinoma for which he had been treated previously by surgery and radiotherapy. The complete remission was achieved after one cycle, although due to toxicity no further gemcitabine-cisplatin treatment was given. The CR lasted for two months. The second patient who achieved a CR had metastatic esophageal adenocarcinoma, with pleuritis carcinomatosa, lymph node metastasis and possibly liver metastasis. Prior treatment consisted of surgery and radiotherapy. This patient obtained a partial remission after two cycles improving to a complete remission after five cycles. The CR lasted for another three months. Interestingly, three out of five patients with esophageal cancer, one squamous (PR) and two adenocarcinoma (PR and CR) responded.
Discussion
The gemcitabine-cisplatin combination chemotherapy is an active treatment in patients with solid tumors such as advanced NSCLC, ovarian cancer and HNSCC. In this schedule finding study we observed sequence dependent cytotoxic effects for this combination. Paired analysis of toxicity data using each patient as his/her own control indicated more severe leukopenia and neutropenia when cisplatin was administered before gemcitabine. For the four-hour interval leukopenia was age and gender dependent. This is in accordance with previous studies with gemcitabine alone, showing age and gender differences in the pharmacokinetic parameters of gemcitabine [33] . The overall clearance of gemcitabine is approximately 25% less for women than for men, resulting in higher plasma drug levels, while this effect is exaggerated by age. The sequence dependent cytotoxicity was significant at the 24-hour time interval. The underlying mechanisms for this sequence dependent effect are not known. Although the results were obtained in a relatively small population with various tumor types and pretreatment, the schedule dependent differences were not related to tumor type or prior treatment, besides patients served as their own control. The observed schedule dependency warrants further evaluation in a randomized study. The results of the simultaneously performed pharmacological study may offer an explanation. Recently, our group described that the schedule in which cisplatin was administered 24 hours before gemcitabine produced the best pharmacological profile: the highest dFdCTP accumulation in mononuclear cells and the highest total Pt levels in plasma [7] , which might be related to the enhanced cytotoxicity observed with this regimen. A possible mechanism could be the inhibitory effect of cisplatin on ribonucleotide reductase [34] , causing a depletion of deoxycytidine-triphosphate (dCTP) pools. Since dCTP can inhibit deoxycytidine kinase (dCK; the rate-limiting enzyme in gemcitabine phosphorylation) [8] this might result in both, an enhanced gemcitabine phosphorylation and activation, and less competition with the gemcitabine-triphosphate (dFdCTP) for incorporation into DNA. Furthermore, gemcitabine might inhibit the nucleotide excision repair of Pt-DNA adducts, because both deoxyribonucleotide and ribonucleotide pools, essential for optimal functioning of DNA repair, are disturbed by gemcitabine [2] . Previously, it has been shown that the extent of DNA adduct repair was inversely related to the nadir white blood cell count [35] . Pharmacologic explanations may also involve competitive inhibition for common metabolic pathways, since both cisplatin and gemcitabine are principally cleared by metabolic mechanisms [19, 33, 36, 37] .
The importance of scheduling for gemcitabine itself has been shown in phase 1 studies [8, 38, 39] . The schedule of gemcitabine (800-1500 mg/m 2 ) given once weekly, two or three times in three-to four-week intervals is now generally accepted as the most active one. The question of the optimal administration schedule for cisplatin has been addressed in a number of clinical trials [40] . The data on the optimal schedule are less conclusive, but suggest that the fractionated delivery approach, i.e., cisplatin administration on day 1 and 8 at a four-weekly cycle, is the best method of drug delivery. Although, there are no data available comparing a one day cisplatin and the day 1 and 8 cisplatin regimen, the day 1 and 8 regimen is much less toxic than daily fractionation of cisplatin per cycle [41] . This day 1 and 8 regimen might in case of combination chemotherapy be superior to the one day regimen in order to enhance the synergism between the two agents.
Recently, the influence of different gemcitabinecisplatin schedules on toxicity and drug delivery was reviewed in patients with NSCLC [11] . In six phase II studies gemcitabine was given on days 1, 8, and 15 of a 28-day cycle. The scheduling of cisplatin varied and was given either once, on day 1 [20] , day 2 [23] , day 15 [1, 21] , or on days 1, 8, and 15 [11, 22] . The regimen in which cisplatin was given on day 15 only was associated with both the highest percentage of cycles containing gemcitabine at full dose (75%) and the highest percentage of cycles in which there were no omissions of gemcitabine infusions (including infusions with dose reductions); 83% for the day 15 regimen as compared to 32%, 55% and 72% for the day 1, day 2, and days 1, 8, and 15 cisplatin regimens, respectively. For our regimen (cisplatin on days 1 or 2 and day 8 or 9), omission of gemcitabine administration was not necessary in 51% of administered cycles. Omissions of gemcitabine needed to be performed on day 15 because of myelosuppression; mainly trombocytopenia. It is postulated that the time interval of seven days after cisplatin administration before gemcitabine administration is insufficient to allow for platelet recovery, while the 14-day interval used in two day 15 cisplatin studies allowed platelet recovery to take place [11] . This indicates that for the cisplatingemcitabine combination, cisplatin scheduling plays an important role in the hematological toxicity pattern, with the cisplatin day 1 and 8 regimen tending to be more toxic than the cisplatin day 15 regimen. However, the relatively low percentage of cycles in which gemcitabine was given three times per cycle in our study might partly be explained by the fact that most patients were heavily pretreated and dose reduction was not foreseen. In the current phase I study grade 3 and 4 trombocytopenia was seen in 66% of patients and grade 3 and 4 leukopenia in 46% of patients. The incidence of grade 3 and 4 trombocytopenia and leukopenia in the phase II studies in patients with non-small-cell lung cancer appeared relatively similar and ranged from 26%-52% and from 18.8%-46.6%, respectively [11] . Although, in our study leukopenia was the most severe when cisplatin was administered 24 hours prior to gemcitabine, the toxicity of the different schedules was manageable and did not significantly affect continuation of the study.
Three prospective randomized trials have already confirmed the efficacy of the gemcitabine plus cisplatin combination in NSCLC [24] [25] [26] [27] . In the present phase I study objective responses were observed in NSCLC as well as in ovarian, HNSCC, adenocarcinoma of unknown primary and esophageal cancer. The latter observation in esophageal cancer is noteworthy and warrant further study. Although in patients with advanced esophageal cancer response rates between 35% and 55% have been observed for various cisplatin based combination regimens [42] , treatment for this disease remains unsatisfactory. Based on the pharmacodynamics studied in many of these patients [7] the sequence with cisplatin 24 hours prior to gemcitabine was chosen for further evaluation and based on the obtained response data a phase II study has been started in patients with upper gastrointestinal tumors. It was not possible to draw conclusions on scheduling and response in this study since patients with different tumor types were studied.
In conclusion, for all four cisplatin-gemcitabine combinations, myelosuppression was the most impor-tant toxicity. Leukopenia was more pronounced for the schedules in which cisplatin preceded gemcitabine as compared to the reversed sequences, however in all schedules toxicity was manageable. Encouraging responses were observed in mostly pretreated, different solid tumors, such as ovarian cancer, adenocarcinoma of unknown origin and esophageal cancer. Also based on pharmacodynamic data, a phase II study with the regimen cisplatin 24 hours prior to gemcitabine is currently ongoing in patients with advanced gastric and esophageal cancer.
